Drug Safety The term "Drug Safety" refers to the frequency of adverse drug effects that are treatment emergent, meaning that they either appear during treatment and were not present prior to treatment or that they worsen relative to the pretreatment state. These adverse effects can be physical or laboratory toxicity that may be related to the drug. Drug safety is the frequency of adverse medication effects that occur during treatment and were not evident before to therapy, or that worsen during treatment as opposed to the pretreatment condition (i.e., physical or laboratory toxicity that may be connected to the drug). The possibility of negative consequences associated with medicine administration is referred to as drug safety. The process of determining a medication's safety profile starts early on with in vitro and in vivo toxicity research, continues through clinical trials leading up to drug approval, and continues after approval with targeted post-marketing studies or more broad pharmacovigilance initiatives.
Vladlen Slepak
University of Miami School of Medicine, United States
Axel H Schonthal
University of Southern California, United States
Bernd Blobel
University of Regensburg, Germany
Consolato M Sergi
University of Alberta, Canada
Luis Jesus Villarreal Gomez
Universidad Autónoma de Baja California, Mexico
Anil Pareek
Anand Pharmacy College, India
Saad Tayyab
UCSI University, Malaysia
Lan Wang
Paretor LLC, United States
Ravi P Sahu
Wright State University, United States
Bhasker Sambar
Alvogen Inc, United StatesSubmit your abstract Today
Title : Development of novel drug delivery pathways enabled by perillyl alcohol (NEO100), A monoterpene with multifaceted biomedical applications
Axel H Schonthal, University of Southern California, United States
Title : From marker to mechanism: Ligand discovery enables functional analysis of OR51E1, an ectopic olfactory receptor, in prostate cancer
Vladlen Slepak, University of Miami School of Medicine, United States
Title : Hepatotoxic botanicals-shadows of pearls
Consolato M Sergi, University of Alberta, Canada
Title : Tailored cellular environments to enable drug design
Lan Wang, Paretor LLC, United States
Title : Personalized and Precision Medicine (PPM) as a unique healthcare model based on design-inspired biotech- & biopharma-driven applications to secure the human healthcare and biosafety
Sergey Suchkov, N D Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, InMedStar and Biona, Russian Federation
Title : Precision diagnostics: Effectiveness of innovative imaging technologies for early detection of lung cancers
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : Principles and standards for managing healthcare transformation towards personalized, preventive, predictive, participative precision medicine ecosystems
Bernd Blobel, University of Regensburg, Germany
Title : Biocompatible synthesis of non crystalline iron oxide nanoparticles with stable colloidal properties
Lan Wang, Paretor LLC, United States
Title : Design and characterization of gum arabic buccal films for protein drug delivery
Krisztian Pamlenyi, University of Szeged, Hungary
Title : Hydrogen sulfide in sepsis: From bench to bedside
Madhav Bhatia, University of Otago, New Zealand